AEON Biopharma (AEON) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AEON Biopharma (AEON) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 66.7% versus a loss of 85.3%. Radiopharm Theranostics is the larger company by market cap ($16.2 million vs $15.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | RADX |
|---|---|---|
| Share price | $0.31 | $1.11 |
| Market cap | $15.46M | $16.20M |
| 1-day change | -0.40% | -3.48% |
| YTD return | -71.70% | -78.74% |
| 1-year return | -66.71% | -85.27% |
| EPS (TTM) | $-4.39 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $16.25 |
| 52-week low | $0.177 | $1.00 |
| Distance from 52-week high | -78.62% | -93.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +487.10% | +1430.63% |
| Average volume | 8.59M | 84.72K |
| Shares outstanding | 49.88M | 14.59M |
| Employees | 8 | 14 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AEON has outperformed RADX by 18.6 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Healthcare · Biotechnology · 8 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Healthcare · Biotechnology · 14 employees
AEON vs RADX FAQ
Which is bigger, AEON Biopharma or Radiopharm Theranostics?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $16.20M compared with $15.46M for AEON Biopharma (AEON).
Which stock has performed better over the past year, AEON or RADX?
AEON returned -66.71% over the past 12 months, compared with -85.27% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.